Identifying Best Approach in Improving Quality of Life and Survival After a Donor Stem Cell Transplant in Older, Medically Infirm, or Frail Patients With Blood Diseases
Seamless Phase II-Phase III Randomized Clinical Trial to Identify and Confirm the Most Promising Novel Intervention to Alleviate Morbidity and Mortality After Allogeneic Hematopoietic Cell Transplantation Among Older, Medically Infirm, or Frail Patients With Hematological Diseases
Sponsor: Fred Hutchinson Cancer Center
Terminated
Study terminated due to meeting interim analysis futility endpoint. No difference was found between two treatment arms at interim analysis of primary outcome.
Other terminated trials from Fred Hutchinson Cancer Center
This PHASE2/PHASE3 trial investigates Hematopoietic and Lymphoid Cell Neoplasm and Non-Neoplastic Hematologic and Lymphocytic Disorder and is currently terminated or withdrawn. Fred Hutchinson Cancer Center leads this study, which shows 30 recorded versions since 2019 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
30 versions recorded-
Feb 2026 — Present [monthly]
Terminated PHASE2/PHASE3
Status: Active Not Recruiting → Terminated
-
Jul 2025 — Feb 2026 [monthly]
Active Not Recruiting PHASE2/PHASE3
-
Feb 2025 — Jul 2025 [monthly]
Active Not Recruiting PHASE2/PHASE3
Status: Recruiting → Active Not Recruiting
-
Sep 2024 — Feb 2025 [monthly]
Recruiting PHASE2/PHASE3
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE2/PHASE3
▶ Show 25 earlier versions
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE2_PHASE3
-
Feb 2024 — Jun 2024 [monthly]
Recruiting PHASE2_PHASE3
-
Jun 2023 — Feb 2024 [monthly]
Recruiting PHASE2_PHASE3
-
Mar 2023 — Jun 2023 [monthly]
Recruiting PHASE2_PHASE3
-
Feb 2023 — Mar 2023 [monthly]
Recruiting PHASE2_PHASE3
-
Sep 2022 — Feb 2023 [monthly]
Recruiting PHASE2_PHASE3
-
Jul 2022 — Sep 2022 [monthly]
Recruiting PHASE2_PHASE3
-
May 2022 — Jul 2022 [monthly]
Recruiting PHASE2_PHASE3
-
Dec 2021 — May 2022 [monthly]
Recruiting PHASE2_PHASE3
-
Nov 2021 — Dec 2021 [monthly]
Recruiting PHASE2_PHASE3
-
Oct 2021 — Nov 2021 [monthly]
Recruiting PHASE2_PHASE3
-
Sep 2021 — Oct 2021 [monthly]
Recruiting PHASE2_PHASE3
-
Jun 2021 — Sep 2021 [monthly]
Recruiting PHASE2_PHASE3
-
Mar 2021 — Jun 2021 [monthly]
Recruiting PHASE2_PHASE3
-
Jan 2021 — Mar 2021 [monthly]
Recruiting PHASE2_PHASE3
-
Oct 2020 — Jan 2021 [monthly]
Recruiting PHASE2_PHASE3
-
Sep 2020 — Oct 2020 [monthly]
Recruiting PHASE2_PHASE3
-
Aug 2020 — Sep 2020 [monthly]
Recruiting PHASE2_PHASE3
-
May 2020 — Aug 2020 [monthly]
Recruiting PHASE2_PHASE3
-
Jan 2020 — May 2020 [monthly]
Recruiting PHASE2_PHASE3
-
Oct 2019 — Jan 2020 [monthly]
Recruiting PHASE2_PHASE3
-
Sep 2019 — Oct 2019 [monthly]
Recruiting PHASE2_PHASE3
Status: Not Yet Recruiting → Recruiting
-
Aug 2019 — Sep 2019 [monthly]
Not Yet Recruiting PHASE2_PHASE3
-
Apr 2019 — Aug 2019 [monthly]
Not Yet Recruiting PHASE2_PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Fred Hutchinson Cancer Center
- National Cancer Institute (NCI)
- National Institutes of Health (NIH)
For direct contact, visit the study record on ClinicalTrials.gov .